Home
Durvalumab – Cancer Drug Reimbursement, October 2026

Durvalumab – Cancer Drug Reimbursement, October 2026

Durvalumab (Imfinzi, AstraZeneca) has been approved for reimbursement in the Republic of Ireland through the Online Drug Management System (ODMS) in October 2026 for a new oncology indication.4

The approved indication is primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), in combination with carboplatin and paclitaxel (chemotherapy doublet). This reflects an extension of durvalumab’s reimbursement in Ireland.

References – Republic of Ireland

4. Cancer Drugs Approved for Reimbursement. Health Service Executive (HSE). October 2026. https://assets.hse.ie/media/documents/Cancer_Drugs_Approved_for_Reimbursement.pdf

Add Your Heading Text Here

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.